文献速递肿瘤 PET/CT核素与放射性配体治疗

数字化90Y PET显像在系统性成纤维细胞激活蛋白抑制剂放射性核素治疗剂量学中的病灶定量准确性

Lesion Quantification Accuracy of Digital 90Y PET Imaging in the Context of Dosimetry in Systemic Fibroblast Activation Protein Inhibitor Radionuclide Therapy.
PubMed 文献 · J Nucl Med · 2022-08-18

本研究用两种肿瘤模体填充90Y溶液,在数字化硅光电倍增器PET/CT系统上评估病灶定量的最低可探测与最低可定量活度浓度,并考察采集时间与平滑水平的影响。结果显示40 mm病灶在临床15分钟采集下最低可探测与最低可定量活度浓度均为0.12 MBq/mL,≥30 mm病灶可准确量化,仅10 mm球体两者差异明显(0.43 vs 1.97 MBq/mL)。3例90Y-FAPI治疗患者的肿瘤剂量学显示可获得可靠精度的吸收剂量估计。

要点

  • 40 mm病灶、15分钟采集时最低可探测与最低可定量活度浓度均为0.12 MBq/mL。
  • ≥30 mm病灶可准确量化,仅10 mm球体最低可探测与最低可定量活度浓度差异明显(0.43 vs 1.97 MBq/mL)。
  • 两种定量方法之间未观察到明显差异。

核心结论

  • 对于90Y-FAPI治疗患者中预期观察到的病灶大小和活度浓度,可实现具有合理准确性的定量。
  • 需要进一步的剂量学研究来充分探究90Y-FAPI治疗的疗效和安全性。

研究设计与样本

  • 用两种肿瘤模体填充90Y溶液,采用不同球体活度浓度和恒定的信号本底比40。
  • 在数字化硅光电倍增器PET/CT系统上确定最低可探测活度浓度,并研究其与采集时间(每床位15 vs 30分钟)和平滑水平(全通 vs 5 mm高斯滤波)的关系。
  • 在不同活度浓度下评估定量准确性,以估计基于轮廓和基于过大感兴趣区的定量方法的最低可定量活度浓度,图像衍生与真实活度浓度之间±20%偏差范围视为可接受。
  • 呈现3例接受90Y-FAPI治疗患者的肿瘤剂量学,以将模体结果投射到临床场景。

主要发现

  • 对于40 mm病灶和临床采集时间15分钟,最低可探测和最低可定量活度浓度均为0.12 MBq/mL。
  • 对于大于或等于30 mm的病灶大小,可检测病灶的准确量化是可行的。
  • 仅对于最小的10 mm球体,最低可探测和最低可定量活度浓度差异显著(0.43 vs 1.97 MBq/mL)。
  • 两种定量方法之间未观察到明显差异。
  • 对于所研究的肿瘤,可获得具有可靠准确性的吸收剂量估计。

关键数值与推荐

  • 图像衍生与真实活度浓度之间±20%偏差范围被视为可接受。
  • 模体信号本底比为40。
  • 40 mm病灶、15分钟采集时最低可探测与最低可定量活度浓度均为0.12 MBq/mL。
  • 10 mm球体最低可探测活度浓度为0.43 MBq/mL,最低可定量活度浓度为1.97 MBq/mL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步的剂量学研究来充分探究90Y-FAPI治疗的疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapy with 90Y-labeled fibroblast activation protein inhibitors (90Y-FAPIs) was recently introduced as a novel treatment concept for patients with solid tumors. Lesion and organ-at-risk dosimetry is part of assessing treatment efficacy and safety and requires reliable quantification of tissue uptake. As 90Y quantification is limited by the low internal positron-electron pair conversion rate, the increased effective sensitivity of digital silicon photomultiplier-based PET/CT systems might increase quantification accuracy and, consequently, allow for dosimetry in 90Y-FAPI therapy. The aim of this study was to explore the conditions for reliable lesion image quantification in 90Y-FAPI radionuclide therapy using a digital PET/CT system. Methods: Two tumor phantoms were filled with 90Y solution using different sphere activity concentrations and a constant signal-to-background ratio of 40. The minimum detectable activity concentration was determined, and its dependence on acquisition time (15 vs. 30 min per bed position) and smoothing levels (all-pass vs. 5-mm gaussian filter) was investigated. Quantification accuracy was evaluated at various activity concentrations to estimate the minimum quantifiable activity concentration using contour-based and oversized volume-of-interest-based quantification approaches. A ±20% deviation range between image-derived and true activity concentrations was regarded as acceptable. Tumor dosimetry for 3 patients treated with 90Y-FAPI is presented to project the phantom results to clinical scenarios. Results: For a lesion size of 40 mm and a clinical acquisition time of 15 min, both minimum detectable and minimum quantifiable activity concentrations were 0.12 MBq/mL. For lesion sizes of greater than or equal to 30 mm, accurate quantification was feasible for detectable lesions. Only for the smallest 10-mm sphere, the minimum detectable and minimum quantifiable activity concentrations differ substantially (0.43 vs. 1.97 MBq/mL). No notable differences between the 2 quantification approaches were observed. For the investigated tumors, absorbed dose estimates with reliable accuracy were achievable. Conclusion: For lesion sizes and activity concentrations that are expected to be observed in patients treated with 90Y-FAPI, quantification with reasonable accuracy is possible. Further dosimetry studies are needed to thoroughly investigate the efficacy and safety of 90Y-FAPI therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kersting D, Jentzen W, Jeromin D, et al. Lesion Quantification Accuracy of Digital 90Y PET Imaging in the Context of Dosimetry in Systemic Fibroblast Activation Protein Inhibitor Radionuclide Therapy. J Nucl Med. 2022. PMID: 35981898. doi:10.2967/jnumed.122.264338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。